Co-Founder, President & CEO


Passionate about improving patient care and enabling increased access to innovative medicines towards improved healthcare outcomes

Niven R. Narain is Co-founder, President & CEO of Berg, a Boston-based biopharma company driving the next generation of drugs and diagnostics by combining patient-driven biology and AI to unravel actionable disease insight. He has overseen development of Berg’s clinical stage assets and pipeline and forged strategic partners with industry, academia, and US and UK governments. Narain is most passionate about improving patient care and enabling increased access to innovative medicines to improved healthcare outcomes.

He is inventor of Berg’s flagship Interrogative Biology, platform that created and guided a deep pipeline of products in oncology, diabetes, and CNS diseases, namely BPM 31510 in Phase 2 trials for cancer. Narain speaks at many international meetings on medicine and technology and his research has been published in Nature Medicine and Cell among others with leading collaborators from academia, NIH, and DoD.  He serves on the NASA/Gene Lab Steering Committee and works closely with DoD leadership on breast and prostate cancer initiatives.

Narain is an inventor on a patent portfolio of over 550 pending patent applications and over 100 issued patents in the US and internationally, covering multiple disease areas and AI-based technologies.  He received his BS/BA in Biochemistry and Philosophy from St. John’s University, NY, obtained PhD training in cancer biology and performed clinical dermatology research at the University of Miami Miller School of Medicine where he served as Director of Cutaneous Oncology Research before moving to Boston.  Niven is a recipient of the Sylvester Cancer Center’s Zubrod Prize, an NIH/NIDDK Award of Excellence and was named to the Boston Business Journal top 40 leaders under 40 in 2014. Narain remains active in leadership and community outreach, having served as a mentor to many high school, college, and graduate/medical students in the Intel, Upward Bound, and NIH Howard Hughes Medical Internship programs.  He serves as a St. John’s University Boston Chapter alumni advisor and is an active member of the Trinity Church Boston.


DAY 1 / ‏‏‎ ‎

09:00 AM - 09:40 AM
Plenary View Session

Executive Viewpoints Debate: What Will it Take to Make the Use of AI/ML Tools Scalable?

  • How do you translate AI/ML technology into patient impact
    • Better treatments
    • Higher quality outcomes
    • Less adverse effect
  • Streamlining processes enterprise-wide
Dimitris K. Agrafiotis, PhD, Chief Information Officer, Novartis Institutes for BioMedical Research (NIBR)
Niven R. Narain, Ph.D, Co-Founder, President & CEO, BERG
Andrew Radin, CEO & Co-Founder, twoXAR Pharmaceuticals

Never miss an announcement

/* */